Rendering of the new build in Hamilton, Ontario. (Credit: OmniaBio)
October 17, 2024 08:00 AM EDTUpdated 08:20 AM
Manufacturing

Cana­di­an CD­MO broad­ens CGT foot­print with new $145M fa­cil­i­ty 

Anna Brown

News Reporter

CD­MO Om­ni­aBio on Thurs­day opened a com­mer­cial-stage cell man­u­fac­tur­ing fa­cil­i­ty that has AI ca­pa­bil­i­ties worth around CAD $200 mil­lion ($145 mil­lion) in its home­town of …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

No­var­tis pays $70M up­front to li­cense Chi­nese biotech’s an­ti­tu­mor drug

Sanofi in­vests in new ra­di­oli­gand part­ner Ora­no Med, buy­ing 16% stake for €300M

FDA ap­proves Ab­b­Vie's 24-hour Parkin­son's in­fu­sion ther­a­py af­ter two CRLs

First clin­i­cal test of RNA edit­ing re­stores miss­ing pro­tein in ge­net­ic dis­ease, Wave says

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times